These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 10699953

  • 1. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR, Tortora G.
    Int J Cancer; 2000 Mar 01; 85(5):710-5. PubMed ID: 10699953
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes.
    Ciardiello F, Pepe S, Bianco C, Baldassarre G, Ruggiero A, Bianco C, Selvam MP, Bianco AR, Tortora G.
    Int J Cancer; 1993 Feb 01; 53(3):438-43. PubMed ID: 8094073
    [Abstract] [Full Text] [Related]

  • 4. Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.
    Tagliaferri P, Tortora G, Guarrasi R, Damiano V, Ruggiero A, Morelli D, Caraglia M, Bianco R, di Isernia G, Pepe S, Arteaga CL, Langton-Webster BC, Bianco AR, Ciardiello F.
    Clin Cancer Res; 1996 Jan 01; 2(1):207-14. PubMed ID: 9816108
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Kelland LR, Abel G.
    Cancer Chemother Pharmacol; 1992 Jan 01; 30(6):444-50. PubMed ID: 1356649
    [Abstract] [Full Text] [Related]

  • 13. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
    Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A.
    Am J Clin Oncol; 2003 Feb 01; 26(1):50-4. PubMed ID: 12576925
    [Abstract] [Full Text] [Related]

  • 14. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
    Merlin JL, Barberi-Heyob M, Bachmann N.
    Ann Oncol; 2002 Nov 01; 13(11):1743-8. PubMed ID: 12419746
    [Abstract] [Full Text] [Related]

  • 15. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F.
    Clin Cancer Res; 1999 Apr 01; 5(4):875-81. PubMed ID: 10213224
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.